Brazikumab Induction Dose

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Crohn's DiseaseIBDUlcerative Colitis

Phase 2

Open-label Extension Study of Brazikumab in Ulcerative Colitis

TerminatedNCT04277546

AstraZenecaUlcerative Colitis

Start: 2020-03-03End: 2023-10-10Updated: 2026-06-23

Phase 3

Open-label Extension Study of Brazikumab in Crohn's Disease

TerminatedNCT03961815

AstraZenecaCrohn's Disease, IBD

Start: 2020-01-06End: 2023-09-19Updated: 2026-04-01

Related Papers

Antibodies to watch in 2020.

2020-01-01328 citations